Best Piramal Group Stocks in India

Piramal Group is an Indian business group led by Ajay Piramal, with major interests in pharma, financial services, real estate, and social impact initiatives. It is headquartered in Mumbai and presents itself as focused on “Advancing Bharat” through business growth and inclusion. Key group businesses include Piramal Pharma, Piramal Finance, Piramal Enterprises, and Piramal Realty.

Piramal stocks refer to the companies associated with the Piramal Group and its financial and healthcare businesses. In simple terms, Piramal stocks are shares of companies linked to the Piramal Group. Their performance depends on sector trends in finance and healthcare, as well as broader market conditions and company-specific factors.

1. Piramal Finance Ltd: Piramal Finance Ltd is a non-banking financial company offering housing finance, corporate lending, and retail loans. It focuses on real estate financing and diversified lending segments, with performance linked to credit demand, asset quality, and interest rate trends in the financial sector.
2. Piramal Pharma Ltd: Piramal Pharma Ltd operates across contract development and manufacturing, complex generics, and consumer healthcare. It serves global markets through manufacturing and research capabilities, with performance driven by pharma demand, exports, regulatory approvals, and growth in the healthcare and pharmaceutical industries.

Here is how you can invest in the best Piramal Group stocks:

1. Open a demat/trading/stockbroker account. You can open a demat account with smallcase!
2. Conduct thorough research into the top Piramal Group stocks in India using Tickertape Stocks Screener. The screener offers over 200 built-in filters, allowing investors to select parameters and generate a Piramal share list.
3. Place a ‘Buy’ Order on the top Piramal Group stocks that align with your investment thesis.

• Exposure to two different sectors: Piramal Group stocks give exposure to both financial services and pharmaceuticals through Piramal Finance Ltd and Piramal Pharma Ltd. This matters because the two businesses are driven by different demand cycles, so the investment case is not tied to only one industry.
• Established business scale: Piramal Pharma crossed the US$ 1 bn revenue milestone in FY2025, which signals meaningful operating scale across its CDMO, complex hospital generics, and consumer healthcare businesses. A larger revenue base can indicate a stronger market presence and broader customer reach.
• Ongoing growth and capital access: Piramal Finance continues to access funding markets to support growth. The company was targeting about ₹150 bn of borrowing between December and March as part of a broader funding plan, while market reports also pointed to a $400 mn borrowing in early 2026. This shows the company’s ability to raise capital for business expansion.
• Diversified business model within the group: The group is not dependent on a single revenue stream. Piramal Finance operates in home loans, business loans, personal loans, and wholesale real estate-linked lending, while Piramal Pharma has multiple business lines across global pharma services and products. That diversification can help reduce dependence on one narrow product segment.

• Profitability can fluctuate: Piramal Pharma reported a ₹136 cr. loss in Q3 FY26, with the company linking the weakness to customer destocking in a large on-patent product, slower early-stage order inflows, and regulatory delays. This shows that even with revenue scale, earnings can still be uneven from quarter to quarter.
• Sector-specific pressure remains high: The two listed businesses face very different risks. Financial services are affected by borrowing costs, credit quality, and lending cycles, while pharma is exposed to regulatory approvals, export demand, customer orders, and global healthcare conditions. Investors need to assess both sectors separately rather than treating the group as one simple theme.
• Dependence on external funding in finance: Piramal Finance relies on continued borrowing to fund lending growth. The company was raising a large amount through loans, local bonds, securitisation, external borrowings, and multilateral sources. If funding costs rise or liquidity conditions tighten, margins and growth can come under pressure.
• Execution risk in expansion plans: Growth plans can create upside, but they also raise expectations. Piramal Pharma has said it is targeting $2 bn revenue by FY30 through organic expansion. That makes execution, customer wins, operating leverage, and margin improvement important factors to track over the next few years.

• Understand which business you are buying: Piramal Finance and Piramal Pharma are exposed to very different business drivers. Piramal Finance is tied to lending growth, asset quality, and funding conditions, while Piramal Pharma depends more on manufacturing demand, exports, regulatory clearances, and product mix. This difference should shape how the stock is evaluated.
• Track revenue and profit together: Revenue growth alone is not enough. Piramal Pharma crossed US$ 1 bn revenue in FY2025, but it also reported a quarterly loss in FY26. Investors should therefore look at margins, EBITDA trends, and profit consistency rather than only topline growth.
• Watch leverage and funding mix: For Piramal Finance, the borrowing profile matters because it directly affects growth and profitability. The company wanted most of its borrowing to be local, which suggests that the cost and source of funds remain important variables.
• Follow sector-level triggers: Piramal Pharma can be influenced by customer destocking, biopharma funding conditions, and regulatory timelines, while Piramal Finance can be influenced by loan demand and real-estate-linked lending trends. Sector triggers often explain stock movements better than broad-group branding.
• Assess risk tolerance before taking exposure: Piramal Group stocks may suit investors comfortable with sector-specific volatility in finance and pharma. Since both businesses operate in regulated and cycle-sensitive spaces, the movement of the Pel share price on NSE can depend on both companies’ execution and external conditions.